Not for release, publication or distribution in the United States of America, the United Kingdom, The European Economic Area or Australia
This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular, this release and the information contained therein is not being issued and may not be distributed in the United States of America, the United Kingdom, The European Economic Area or Australia and does not constitute an offer of securities for sale in such or any other countries.
London, March 29, 2017. Rapid Nutrition PLC (SIX: RAP), the international organic healthcare company, announced today that the company’s shares will start trading as of today on the SIX Swiss Exchange (“SIX”) under the ticker symbol “RAP”. The trading start follows the approval for listing and trading which was granted by the SIX Exchange Regulation.
The company's shares will trade in EUR and the initial trading price has been set at EUR 2.29 which is approximately CHF 2.45 or AUD 3.26 per share. This initial price translates to a market capitalization based on the listed shares of approximately EUR 53 million and CHF 57 million, respectively. Application for inclusion of the Rapid Nutrition shares (SIX: RAP) in the Swiss Performance Index (SPI®) will be made.
Rapid Nutrition's listing at the SIX Swiss Exchange should permit investors a better stock performance comparison with other renowned global brands and market leaders and offers the potential of an adequate valuation of Rapid Nutrition with a stronger opportunity to raise capital for global expansion plans. The listing at SIX also ensures that Rapid Nutrition will be traded at what the exchange considers to be the most prominent stock market in the Life Sciences sector in Europe.
“We genuinely appreciate our investors' support, dedication and patience throughout this successful process of getting re-listed and we are convinced to have selected the ideal European exchange to bolster Rapid Nutrition's profile, investment case and success across the globe,” commented Simon St. Ledger, Managing Director of Rapid Nutrition.
Copies of the Listing Memorandum are available free of charge at the offices of Rapid Nutrition at 2nd Floor, 145-157 St. John Street, London, United Kingdom, EC1V 4PW (phone: +61 7 3200 4222; fax: +61 7 3200 4288; mail: email@example.com) during regular business hours. The Listing Memorandum is the only authoritative source of information on the listing of the company's shares.
Important information for media
About Rapid Nutrition PLC
Rapid Nutrition is a natural healthcare company focused on the research, development and production of a range of life science products. The company was established based on its weight loss supplement range which is exported worldwide and offers consumers a growing range of health and well-being solutions to meet existing and emerging societal health concerns, as well as a providing a number of wider services to the life sciences industry.
For more information, please visit www.rnplc.com
For further details, please contact:
Simon St. Ledger, Managing Director
Rapid Nutrition PLC
Phone: +61 7 3200 4222
Andrés Luther, Media Relations
Phone: +41 43 344 4242
Thomas Schneckenburger, Investor Relations
Phone: +41 43 344 4242
This communication expressly or implicitly contains certain forward-looking statements concerning Rapid Nutrition PLC and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of the Rapid Nutrition group to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Rapid Nutrition PLC is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning of article 652a or article 1156 of the Swiss Code of Obligations or a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange.
This media information is not being issued in countries where the public dissemination of the information contained herein may be restricted or prohibited by law. In particular, this media information is not being issue in the United States of America and should not be distributed to U.S. persons or publications with a general circulation in the United States. Any non-compliance with such restrictions may result in an infringement of U.S. Securities Laws. In particular, the securities of Rapid Nutrition PLC have not been registered under the U.S. Securities laws and may not be offered, sold or delivered within the United States or to U.S. persons absent the registration under or an applicable exemption from the registration requirements of the U.S. Securities laws.
This information is for distribution in the United Kingdom only to: persons who (i) are outside the United Kingdom; (ii) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (Order); (iii) are persons falling within Article 48(2) of the Order (certified high net worth individuals); (iv) are persons falling within Article 49(2) of the Order (high net worth companies, unincorporated associations, etc.); (v) are persons falling within article 50(1) of the Order (sophisticated investors); (vi) are persons falling within article 50A(1) of the Order (self-certified sophisticated investors); (vii) are persons falling within article 51 of the Order (associations of high net worth or sophisticated investors); or (viii) are persons to whom it may otherwise lawfully be communicated (all such persons together being Relevant Persons). This media information is only available to Relevant Persons and persons other than Relevant Persons must not act or rely on it.
This media information may not be provided in Australia other than to select investors ("Exempt Investors") who are able to demonstrate that they (a) fall within one or more of the categories of investors under section 708 of the Australian Corporations Act to whom an offer may be made without disclosure under Part 6D.2 of the Australian Corporations Act and (b) are "wholesale clients" for the purpose of section 761G of the Australian Corporations Act.